Biomarkers of inflammation – LBP and TLR— predict progression of knee osteoarthritis in the DOXY clinical trial

Z. Y. Huang, E. Perry, J. L. Huebner, Barry Katz, Y. J. Li, V. B. Kraus

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective: To evaluate systemic inflammatory biomarkers in symptomatic knee osteoarthritis (OA) and their association with radiographic and biochemical OA progression. Methods: Lipopolysaccharide (LPS) binding protein (LBP), soluble Toll-like receptor 4 (sTLR4) and interleukin 6 (IL-6) were measured in plasma of 431 knee OA patients from the doxycycline (DOXY) trial at baseline and 18 months. Plasma lipopolysaccharide and lipopolysaccharide binding protein (LBP) were also measured at 12 months. As a biochemical indicator of disease activity and OA progression, urinary (u) C-telopeptide of Type II collagen (uCTX-II) was measured in samples collected at baseline and 18 months. Change over 16 months in radiographic tibiofemoral joint space width (JSW in mm) and joint space narrowing (JSN≥0.5 mm) were used to indicate radiographic OA progression. Change over 18 months for uCTX-II was used as a secondary outcome. Both univariate and multivariable regression analyses were performed to test the association between Z-score transformed biomarkers and outcomes. Results: Baseline LBP and time-integrated concentration (TIC) of LBP over 12 and 18 months were associated with worsening joint space width (JSW) (parameter estimates: −0.1 to −0.07) and JSN (OR: 1.32 to 1.42) adjusting for treatment group, age, body mass index (BMI) and corresponding baseline radiographic measures. Baseline sTLR4 and TIC over 18 months were associated with change in uCTX-II over 18 months (adjusted parameter estimates: 0.0017 to 0.0020). Results were not modified by treatment with doxycycline. Conclusion: Plasma LBP and sTLR4 were associated with knee OA progression over 16–18 months. These results lend further support for a role of systemic low-grade inflammation in the pathogenesis of knee OA progression.

Original languageEnglish (US)
JournalOsteoarthritis and Cartilage
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Knee Osteoarthritis
Doxycycline
Biomarkers
Toll-Like Receptor 4
Clinical Trials
Inflammation
Joints
Osteoarthritis
Plasmas
Toll-Like Receptor 6
Association reactions
Collagen Type II
Collagen
Lipopolysaccharides
Interleukin-6
Body Mass Index
Age Groups
Regression Analysis
lipopolysaccharide-binding protein
Carrier Proteins

Keywords

  • Biomarkers
  • Inflammation
  • Knee osteoarthritis
  • LBP
  • Path analysis
  • sTLR4

ASJC Scopus subject areas

  • Rheumatology
  • Biomedical Engineering
  • Orthopedics and Sports Medicine

Cite this

Biomarkers of inflammation – LBP and TLR— predict progression of knee osteoarthritis in the DOXY clinical trial. / Huang, Z. Y.; Perry, E.; Huebner, J. L.; Katz, Barry; Li, Y. J.; Kraus, V. B.

In: Osteoarthritis and Cartilage, 01.01.2018.

Research output: Contribution to journalArticle

@article{dc989196269d4a63b1abf8d162975641,
title = "Biomarkers of inflammation – LBP and TLR— predict progression of knee osteoarthritis in the DOXY clinical trial",
abstract = "Objective: To evaluate systemic inflammatory biomarkers in symptomatic knee osteoarthritis (OA) and their association with radiographic and biochemical OA progression. Methods: Lipopolysaccharide (LPS) binding protein (LBP), soluble Toll-like receptor 4 (sTLR4) and interleukin 6 (IL-6) were measured in plasma of 431 knee OA patients from the doxycycline (DOXY) trial at baseline and 18 months. Plasma lipopolysaccharide and lipopolysaccharide binding protein (LBP) were also measured at 12 months. As a biochemical indicator of disease activity and OA progression, urinary (u) C-telopeptide of Type II collagen (uCTX-II) was measured in samples collected at baseline and 18 months. Change over 16 months in radiographic tibiofemoral joint space width (JSW in mm) and joint space narrowing (JSN≥0.5 mm) were used to indicate radiographic OA progression. Change over 18 months for uCTX-II was used as a secondary outcome. Both univariate and multivariable regression analyses were performed to test the association between Z-score transformed biomarkers and outcomes. Results: Baseline LBP and time-integrated concentration (TIC) of LBP over 12 and 18 months were associated with worsening joint space width (JSW) (parameter estimates: −0.1 to −0.07) and JSN (OR: 1.32 to 1.42) adjusting for treatment group, age, body mass index (BMI) and corresponding baseline radiographic measures. Baseline sTLR4 and TIC over 18 months were associated with change in uCTX-II over 18 months (adjusted parameter estimates: 0.0017 to 0.0020). Results were not modified by treatment with doxycycline. Conclusion: Plasma LBP and sTLR4 were associated with knee OA progression over 16–18 months. These results lend further support for a role of systemic low-grade inflammation in the pathogenesis of knee OA progression.",
keywords = "Biomarkers, Inflammation, Knee osteoarthritis, LBP, Path analysis, sTLR4",
author = "Huang, {Z. Y.} and E. Perry and Huebner, {J. L.} and Barry Katz and Li, {Y. J.} and Kraus, {V. B.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.joca.2018.08.005",
language = "English (US)",
journal = "Osteoarthritis and Cartilage",
issn = "1063-4584",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Biomarkers of inflammation – LBP and TLR— predict progression of knee osteoarthritis in the DOXY clinical trial

AU - Huang, Z. Y.

AU - Perry, E.

AU - Huebner, J. L.

AU - Katz, Barry

AU - Li, Y. J.

AU - Kraus, V. B.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Objective: To evaluate systemic inflammatory biomarkers in symptomatic knee osteoarthritis (OA) and their association with radiographic and biochemical OA progression. Methods: Lipopolysaccharide (LPS) binding protein (LBP), soluble Toll-like receptor 4 (sTLR4) and interleukin 6 (IL-6) were measured in plasma of 431 knee OA patients from the doxycycline (DOXY) trial at baseline and 18 months. Plasma lipopolysaccharide and lipopolysaccharide binding protein (LBP) were also measured at 12 months. As a biochemical indicator of disease activity and OA progression, urinary (u) C-telopeptide of Type II collagen (uCTX-II) was measured in samples collected at baseline and 18 months. Change over 16 months in radiographic tibiofemoral joint space width (JSW in mm) and joint space narrowing (JSN≥0.5 mm) were used to indicate radiographic OA progression. Change over 18 months for uCTX-II was used as a secondary outcome. Both univariate and multivariable regression analyses were performed to test the association between Z-score transformed biomarkers and outcomes. Results: Baseline LBP and time-integrated concentration (TIC) of LBP over 12 and 18 months were associated with worsening joint space width (JSW) (parameter estimates: −0.1 to −0.07) and JSN (OR: 1.32 to 1.42) adjusting for treatment group, age, body mass index (BMI) and corresponding baseline radiographic measures. Baseline sTLR4 and TIC over 18 months were associated with change in uCTX-II over 18 months (adjusted parameter estimates: 0.0017 to 0.0020). Results were not modified by treatment with doxycycline. Conclusion: Plasma LBP and sTLR4 were associated with knee OA progression over 16–18 months. These results lend further support for a role of systemic low-grade inflammation in the pathogenesis of knee OA progression.

AB - Objective: To evaluate systemic inflammatory biomarkers in symptomatic knee osteoarthritis (OA) and their association with radiographic and biochemical OA progression. Methods: Lipopolysaccharide (LPS) binding protein (LBP), soluble Toll-like receptor 4 (sTLR4) and interleukin 6 (IL-6) were measured in plasma of 431 knee OA patients from the doxycycline (DOXY) trial at baseline and 18 months. Plasma lipopolysaccharide and lipopolysaccharide binding protein (LBP) were also measured at 12 months. As a biochemical indicator of disease activity and OA progression, urinary (u) C-telopeptide of Type II collagen (uCTX-II) was measured in samples collected at baseline and 18 months. Change over 16 months in radiographic tibiofemoral joint space width (JSW in mm) and joint space narrowing (JSN≥0.5 mm) were used to indicate radiographic OA progression. Change over 18 months for uCTX-II was used as a secondary outcome. Both univariate and multivariable regression analyses were performed to test the association between Z-score transformed biomarkers and outcomes. Results: Baseline LBP and time-integrated concentration (TIC) of LBP over 12 and 18 months were associated with worsening joint space width (JSW) (parameter estimates: −0.1 to −0.07) and JSN (OR: 1.32 to 1.42) adjusting for treatment group, age, body mass index (BMI) and corresponding baseline radiographic measures. Baseline sTLR4 and TIC over 18 months were associated with change in uCTX-II over 18 months (adjusted parameter estimates: 0.0017 to 0.0020). Results were not modified by treatment with doxycycline. Conclusion: Plasma LBP and sTLR4 were associated with knee OA progression over 16–18 months. These results lend further support for a role of systemic low-grade inflammation in the pathogenesis of knee OA progression.

KW - Biomarkers

KW - Inflammation

KW - Knee osteoarthritis

KW - LBP

KW - Path analysis

KW - sTLR4

UR - http://www.scopus.com/inward/record.url?scp=85053153562&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053153562&partnerID=8YFLogxK

U2 - 10.1016/j.joca.2018.08.005

DO - 10.1016/j.joca.2018.08.005

M3 - Article

C2 - 30144513

AN - SCOPUS:85053153562

JO - Osteoarthritis and Cartilage

JF - Osteoarthritis and Cartilage

SN - 1063-4584

ER -